Transplantation of photobiomodulation-preconditioned diabetic stem cells accelerates ischemic wound healing in diabetic rats

Houssein Ahmadi, Abdollah Amini, Fatemeh Fadaei Fathabady, Atarodsadat Mostafavinia, Fatemeh Zare, Roohollah Ebrahimpour-malekshah, Mustafa Neshat Ghalibaf, Matin Abrisham, Fatemehalsadat Rezaei, Richard Albright, Seyed Kamran Ghereishi, Sufan Chien and Mohammad Bayat

Abstract

Background: Diabetic foot ulcer is the most costly and complex challenge for patients with diabetes. We hereby assessed the effectiveness of different preconditioned adipose-derived mesenchymal stem cells (AD-MSCs) and photobiomodulation protocols on treating an infected ischemic wound in type 1 diabetic rats.

Methods: There were five groups of rats: (1) control, (2) control AD-MSCs [diabetic AD-MSCs were transplanted (grafted) into the wound bed], (3) AD-MSC + photobiomodulation in vivo (diabetic AD-MSCs were grafted into the wound, followed by in vivo PBM treatment), (4) AD-MSCs + photobiomodulation in vitro, and (5) AD-MSCs + photobiomodulation in vitro + in vivo.

Results: Diabetic AD-MSCs preconditioned with photobiomodulation had significantly risen cell function compared to diabetic AD-MSC. Groups 3 and 5 had significantly decreased microbial flora correlated to groups 1 and 2 (all, p = 0.000). Groups 2, 3, 4, and 5 had significantly improved wound closure rate (0.4, 0.4, 0.4, and 0.8, respectively) compared to group 1 (0.2). Groups 2–5 had significantly increased wound strength compared to group 1 (all p = 0.000). In most cases, group 5 had significantly better results than groups 2, 3, and 4.

Conclusions: Preconditioning diabetic AD-MSCs with photobiomodulation in vitro plus photobiomodulation in vivo significantly hastened healing in the diabetic rat model of an ischemic infected delayed healing wound.

(Continued on next page)
Introduction
Worldwide, diabetes mellitus (DM) is a persistent, challenging metabolic condition for patients, their families, and the community [1]. An estimated 463 million persons suffer from DM globally; this number is anticipated to increase by 25% in 2030 [2]. Approximately 50% of patients with DM are undiagnosed [3]. Diabetic foot ulcer (DFU) is the most costly and complex challenge for patients with DM [4]. DFU impacts 25% of these people at some point in their lives, and over half of these ulcers become infected [4]. Almost 60% of whole limb amputations are performed in people with DM [5]. In most cases, limb amputations are preceded by an infected DFU [6]. Staphylococcus aureus is the predominant microbe in infected DFUs [7]. Methicillin-resistant Staphylococcus aureus (MRSA) comprises 15–30% of microbial DFUs [7]. Due to overuse of inappropriately prescribed antibiotics, there is an increase in drug-resistant microbes, especially in patients with DFUs [8].

Skin wound healing is an active, natural course of healing that can be separated into the following phases: hemostasis, inflammation, proliferation, and maturation. DM leads to compromised wound repair by disturbances in one or more of the above mentioned phases [9]. Persistent and poorly controlled hyperglycemia, which leads to inflammation, hypoxia, peripheral neuropathy, and ischemia, causes foot deformities and DFU [10, 11]. Compromised injury repair in DM is categorized by decreases in new blood vessel formation, endothelial progenitor cell (EPC) employment, and fibroblast and keratinocyte proliferation and migration [12]. DFUs are considered to be a primary medical challenge [13].

Adipose-derived mesenchymal stem cells (AD-MSCs) could improve DFU repair via boosting re-epithelialization and the creation of granulation tissue, anti-inflammatory and anti-apoptotic effects, and secretion of angiogenic growth factors [14]. Bioactive molecules released by AD-MSC promote new blood vessel formation in an ischemic limb via paracrine actions [15] and improve anti-inflammatory impacts in the injured regions [16]. Despite their potential, barriers should be overcome prior to obtaining the full benefits of AD-MSC. First, restricted transplantation and viability of AD-MSC at the wound place are primary concerns, and substitutions to maximize AD-MSC potential are a major request [17]. Second, autologous cell-based treatments might be restricted by decreasing cellular function related to DM [18]. These documents point out effectiveness of autologous mesenchymal stem cell (MSC) as an alternative treatment in DM might be restricted and some mediations to advance cell action prior application are necessary [17, 19].

Using preconditioning stem cells with photobiomodulation (PBM) is an important strategy to overcome poor engraftment and survival and DM-related impairments in diabetic stem cells. PBM stimulates healing, decreases pain and inflammation [20], and diminishes M1 macrophages in the triggered macrophages [20]. PBM modulates hypoxia-inducible factor (HIF)-1α expression [21], improves regional blood stream, and enhances tissue healing by encouraging angiogenesis [22]. In particular, a combination of PBM plus non-diabetic allograft AD-MSC successfully healed a delayed healing wound in rats with type 2 DM (DM2) [23].

PBM increases the proliferation rate of cultivated cells, as well as MSCs, in vitro without causing cytotoxic effects [24]. Some experiments have shown that preconditioning cells with PBM could be an original non-intrusive tactic for stem cell engraftment, which would improve cell viability and benefit cardiac regenerative therapy and stimulate the paracrine release of MSCs [25].

Recently, in our lab, we have engrafted healthy AD-MSC cells into wounds of diabetic rats [23, 26]. However, in the current probe, we engrafted preconditioned diabetic AD-MSC with PBM into wounds of diabetic rats. We believe the current probe is more closely resembling the clinical situation in which diabetic patients who suffer from DFUs could be treated with their own preconditioned stem cells with PBM. In the existing probe, we initially preconditioned diabetic AD-MSC with PBM in vitro. Next, we assessed different protocols of using AD-MSC and PBM on healing infected ischemic delayed healing wounds in type 1 diabetic rats (DM1). The best protocol of combined administration of PBM and AD-MSC would accelerate the repair course of DFU in diabetic patients.

Materials and methods
Animals and study design
Ethical approval of all techniques on animals was confirmed by the IRB of the Shahid Beheshti University of Medical Sciences (File no: IR.SBMU.MSP.REC.1399.105). The male adult Wistar rats were retained in animal rooms with standard conditions: 12 h dark–12 h synthetic light set, and temperature preserved at 22 ± 2 °C. Initially, we introduced DM1 in 10 adult male Wister rats (in vitro phase). The rats were maintained for 30 days. Next,
adipose tissue was extracted from the lower abdominal region of each rat. Cells were separated from the adipose tissue in the laboratory and were categorized as AD-MSC. These AD-MSCs were cultured and expanded in vitro in high glucose medium (25 mmol/L) and were considered to be the diabetic AD-MSC. The diabetic AD-MSCs were preconditioned with PBM. In vitro lab tests showed a remarkable escalation in cell viability along with significant decreases in population doubling time (PDT) and apoptosis rate of the laser-treated AD-MSC compared to the diabetic AD-MSC. Because of the elevations in blood glucose levels, and severely decreased body weights in the diabetic rats, we were unable to use these rats for further experimentation. Thus, a second experiment (in vivo phase) was performed on an additional 30 rats. These rats were considered to have DM1 for 21 days prior to infliction of delayed healing wounds in them. At this point, these rats (30 rats) were randomly allotted to five groups (n = 6 per group). Group 1 was the control (placebo) rats that received no intervention. In group 2 (control AD-MSC), we grafted (transplanted) the diabetic AD-MSC into the wounds of the rats in this group. Group 3 (AD-MSC + PBM in vivo) received diabetic AD-MSC grafted into the wounds followed by in vivo administration of PBM in the wound area. In the fourth group (AD-MSC + PBM in vitro), diabetic AD-MSCs preconditioned with PBM were transplanted into the wounds. In the fifth group (AD-MSC + PBM in vitro+ in vivo), diabetic AD-MSCs preconditioned with PBM were transplanted into wounds, and each wound was treated with PBM in vivo. Wound closure rate, microbial examination and colony-forming unit (CFU) counts, wound strength, and stereological tests were assessed. Each of the above-mentioned examination was performed in 6 rats. Days 4, 8, 12, and 16 were supposed to be the inflammatory, proliferation, early, and late remodeling phases of the skin wound healing process. Rats were euthanized on day 16, and tensiometerical and histological samples were extracted.

Preparation of diabetic AD-MSC and in vitro culture
We administered an intraperitoneal (IP) injection of streptozotocin (STZ, 40 mg/kg) to each of the 10 adult male Wistar rats for induction of DM1. DM1 was verified when the rats had blood glucose levels higher than 250 mg/dl [27]. All rats were maintained for 30 days to confirm the establishment of the DM1 model [21]. These rats had severe declines in body weight and adipose tissue. Too little adipose tissue was extracted from the lower abdominal region and inguinal pad fat. AD-MSCs were extracted from the adipose tissue by standard protocol, and the cells were cultured in an elevated glucose concentration (25 mmol/l or 450 mg/dl). Flow cytometry technique was utilized to characterize the AD-MSC in terms of MSC cluster of differentiation markers (CD) (CD11b, CD45, CD44H, and CD105) as previously reported [23].

One-time diabetic AD-MSC injection and one-time transplantation of preconditioned diabetic AD-MSC
At 24 h after surgery, 1 × 10^6 passage-4 diabetic AD-MSCs in 300 μl PBS were injected intradermally into eight sites around each wound (Fig. 1). Diabetic AD-MSCs were injected into the wounds of rats in group 2, and preconditioned diabetic AD-MSCs were injected into wounds of rats from groups 4 and 5 [23].

Preconditioning of diabetic AD-MSC with PBM in vitro
1 × 10^4 passage-4 AD-MSCs were seeded in each well of a 24-well plate for each of the three groups: healthy control AD-MSC, diabetic control AD-MSC, and experimental diabetic AD-MSC. Here, red laser alone plus infrared laser alone at two energy densities were used to irradiate the AD-MSC every other day for three sessions according to our previously published protocol [28]. Table 1 lists the in vitro PBM parameters. At 24 h after the last PBM administration, we used MTT, PDT, and apoptosis rate tests to determine the best PBM protocol for preconditioning the diabetic AD-MSC.
MTT test
We used the MTT test to count the numbers of viable cells, and the AD-MSCs were prepared for the MTT test as previously explained [29].

PDT test

\[
PDT = T \times \log_2/(\log N_t - \log N_0)
\]

where \(T\) = AD-MSC culture time, \(N_0\) = initial AD-MSC number, and \(N_t\) = number of harvested AD-MSCs [29].

Acridine orange (AO)/ethidium bromide (EB) staining
We added 200 μl dual fluorescent staining solution that contained 100 μg/ml AO + 100 μg/ml EB (Sigma Aldrich, USA) to each well of the AD-MSC culture plate. Morphology and percentages of live and apoptotic AD-MSCs in five fields were assessed by a fluorescent microscope (Nikon, C-SHG, Japan) and recorded [29].

Table 1 Specifications of in vitro and in vivo photobiomodulation parameters

| Specifications of in vitro photobiomodulation | Specifications of in vivo photobiomodulation |
|---------------------------------------------|---------------------------------------------|
| Laser type | Wavelength (nm) | Power (W) | Duration of each administration (s) | Energy density (J/cm²) | Laser beam diameter (cm) | Laser beam area (cm²) | Power density (W/cm²) |
| Red      | 630            | 0.05      | 46, 92                           | 1.2,2,4               | 1.56                   | 1.91                 | 0.0261                 |
| Near infrared | 810            | 0.05      | 46, 92                           | 1.2,2,4               | 1.56                   | 1.91                 | 0.0261                 |
| Company   | NILTVIR202 Noura Instruments, Tehran, Iran |

Surgery
The 30 diabetic rats underwent surgery as described previously [23]. At first, under general anesthesia and sterile conditions, a bipedicle skin flap (10 × 3.5 cm) was created on the dorsal region of each rat. Next, a 12-mm full-thickness circular excision was generated in the middle of each flap and a silicone made ring frame was fixed around each wound to counteract skin muscle contraction (Fig. 1).

Gross examinations
The rats’ weights and blood sugar levels throughout the project were documented.

Inoculation of MRSA into the wounds and microbiological examination
The rats received injections of MRSA according to a previously published protocol [23]. Briefly, each wound was covered with a topical application of a 100-μl aliquot that contained \(2 \times 10^7\) MRSA (ATCC 25923) just after surgery. Microbiological samples were obtained for
routine microbiological analyses on days 8 and 16, and the numbers of probable bacterial colonies in the wound from each rat were reported as the CFU [23].

**In vivo PBM**
The wounds of the rats in groups 3 and 5 were subjected to PBM in vivo (Fig. 1). Table 1 lists the complete specifications of the in vivo PBM protocol.

**Wound closure rate**
We photographed the wounds on days 0, 4, 8, 12, and 16 and measured the wound surface area by ImageJ software (NIH, USA). The wound closure rate was calculated as follows [26].

\[
\frac{\text{Surface area at day 0 - surface area at day } X}{\text{Surface area at day 0}} \times 100\%.
\]

**Tensiometric examination**
One 5 × 50 mm typical sample from each wound of all the rats was extracted on day 16 and subjected to the deformation rate (0.166 m/s) of a material testing machine. We calculated the bending stiffness (MPa) and stress high load (N/cm²) of the samples [23].

**Histological and stereological analyses**
Neutrophils, macrophages and fibroblasts count, and vascular lengths measurement were examined in 10 randomly selected slides of each rat. Hematoxylin and eosin (H&E)-stained slides were assessed according to the physical dissector method at magnification of ×400 under a light microscope. Special criteria based on two previously published papers [30, 31] were utilized for the abovementioned cell selection, specifically endothelial cells. Collagen fibers were examined semi-descriptively in Mallory’s trichrome staining slides [23].

**Calculation of the cell numbers**

\[
N_v = \frac{\Sigma Q}{(h \times a/f \times \Sigma p)}
\]

where \(N_v\) is the numerical density, \(\Sigma Q\) number of nuclei, \(h\) height of the dissector and \(a/f\) was all counting frame (field) area in each rat.

\(N\) (total of cells in each rat) = \(N_v \times V\)

where \(N_v\) is the numerical density and \(V\) the final total volume.

Estimation of vascular length as a biomarker for angiogenesis = \(2\Sigma Q / (\Sigma P \times a/f)\)

where \(2\Sigma Q\) (total number of the vessels counted per rat)/\(\Sigma P\) (number of counting frames in all fields \(a/f\)) [23].

**Statistical analysis**
Data are shown as mean ± standard deviation (SD). The comparison of body weights and blood sugar values was performed by the \(t\) test. We used one-way analysis of variance (ANOVA), repeated measurement analysis, and least significant difference (LSD) tests for statistical analyses of microbial, wound closure, tensiometrical, and stereological examinations. A logistic regression model fitted to the data was used to estimate the ulcer closure rate (the number of wounds closed/total samples) in each group on day 16. A \(p\) value of < 0.05 was considered significant.

**Results**

**Marker expressions**
Flow cytometry analysis showed that the diabetic AD-MSC cells slightly expressed hematopoietic CD markers CDs11b (0.33%) and CD45 (0.8%) and completely expressed mesenchymal CDs 44H and 105 (100%). The graphs are shown in Additional file 1 (Fig. 7).

**In vitro assay results**
Figure 2 shows the in vitro assay results. All \(p\) values were derived from the LSD test. Briefly, administration of 1.2 J/cm² PBM significantly increased cell survival and significantly decreased PDT and the apoptosis rate in the experimental diabetic AD-MSC group compared with the healthy control AD-MSC and diabetic control AD-MSC groups. Therefore, we selected 1.2 J/cm² PBM for preconditioning the AD-MSC.

**In vivo results**

**Gross observations**
All of the rats had significant elevations in blood glucose levels and reductions in body weight after the STZ injection. Details are shown in Table 2 in Additional file 1.

**MRSA findings**
Figure 3 shows the CFU results in the infected wounds of the study groups. Briefly, all groups with PBM therapy significantly diminished CFUs in the wounds compared (correlated) to the control groups (all, \(p = 0.000\)). However, group 5 had statistically more effective results than the other groups (all, \(p = 0.000\)). Treatment with only AD-MSC was not effective.

**Day 8**
Groups 5 and 3 significantly decreased CFU in the wounds correlated to groups 1, 2, and 4 (all, \(p = 0.000\)) (Fig. 3).

**Day 16**
Groups 5, 4, and 3 significantly decreased the CFU in the wounds correlated to groups 1 and 2 (all, \(p = 0.000\)).
Outcome of wound closure rate examination

All findings are shown in Fig. 4. In days 8, 12, and 16, the results of groups 3, 4, and 5 were statistically better than those of group 1.

Day 4 wound closure rate

Group 3 had a significantly decreased wound closure rate correlated to groups 1 ($p = 0.000$), 2 ($p = 0.016$), and 4 ($p = 0.033$).

Day 8 wound closure rate

Groups 5 ($p = 0.000$), 3 ($p = 0.008$), and 4 ($p = 0.02$) had significantly increased wound closure rates correlated to groups 1 and 2. Group 5 was significantly better than groups 3 ($p = 0.002$) and 4 ($p = 0.001$).

Day 12 wound closure rate

Groups 5 ($p = 0.003$), 3, and 4 ($p = 0.031$) had significantly increased wound closure rates correlated to group 2.
Day 16 wound closure rate
Group 5 was significantly better than group 2 ($p = 0.033$).

Logistic regression analysis at day 16
Figure 4, panel b, shows the corresponding estimated wound closure rate in each group by logistic regression analysis. The highest wound closure rate was observed in group 5 (0.8). The wound closure rates for groups 2, 3, and 4 were 0.4, and for group 1, it was 0.2.

Tensiometrical findings
Groups 2–5 had significantly increased bending stiffness and stress high load in the wounds correlated to group 1 (all, $p = 0.000$).

Bending stiffness and stress high load
Groups 5 and 4 had significantly better bending stiffness and stress high load than groups 3 and 2 (all, $p = 0.000$). The results of group 5 were significantly better than those of group 4 ($p = 0.000$) (Fig. 5).

Outcomes of histological analysis and finding of H&E staining
Photos of histological slides are shown in Additional file 1 (Fig. 8). We found that groups 5 and 2 had significantly modulated inflammatory cells correlated to group 1 (both, $p = 0.000$). Groups 2, 3, 4, and 5 had significantly increased fibroblast counts and vascular length correlated to group 1. The results of group 5 were statistically better than other groups. All results are shown in Fig. 6.

Finding of Mallory’s trichrome staining
Collagen fiber orientation in the control group was mostly mixed. In most cases, they were horizontal in the treatment groups. Collagen fibers in the control group were mostly thin and loose, whereas in groups 2–5, they were thicker and more compact than in the control group. Mallory’s trichrome staining in the study groups is shown in Additional file 1 (Fig. 9).

Discussion
Under normal circumstances, the inflammatory phase of the wound repair is well-coordinated, enduring just within days, and the phases of wound repair advance routinely. But, in DM, the inflammatory phase is prolonged and the entirety of the wounded skin is not reestablished, which results in delayed healing or ulcer formation [32]. Patients with DFU should undergo numerous types of treatments for prolonged periods of time, which are costly, and result in a tremendous financial burden for community and insurance organizations [33].

Scientists have focused on innovative tactics to treat delayed healing wounds [34]. MSC cell-based methods have been proposed as potential treatments for delayed healing wounds. Both in vitro and in vivo animal experiments have shown that AD-MSCs differentiate into different types of skin cells and release bioactive molecules that contribute to wound repair in a paracrine way [35]. Autologous MSCs including AD-MSC have been applied in most of medical and animal probes [34]. AD-MSC could escalate the viability of the adipose graft by regulating the inflammatory and oxidative stress responses [36]. The predominant use of autologous MSCs is legitimized by easier isolation procedures, security, and lack of ethical struggle [37]. So in the current study, we selected an approach toward using autologous stem cell for treating diabetic wounds in future studies.
Despite the benefits, there are numerous problems that preclude stem cell use as a treatment of the wound skin. (1) Elevated blood glucose levels in DM result in the aggregation of advanced glycosylation end products (AGEs). These AGEs suppress proliferation and cause apoptosis of AD-MSC, suppress differentiation of AD-MSC into endothelial cells, and prevent the production of collagen protein, all of which contribute directly to delayed wound healing [38]. (2) Despite the increased use of MSCs in clinical trials, the therapeutic benefits remain insignificant [39] and are partially attributed to the natural restricted illness-adjusting capability of MSCs [39]. On the other hand, tissue damage and the curative body reactions cause secretion of endogenous hazard signals [40, 41], which change the immune micromilieu [42]. Hazard signals adversely affect healing in numerous damaged organs [43]. Therefore, the discovery of novel approaches that increase the capabilities of the MSCs is a dynamic field of biological investigation that has medical significance [39]. MSCs are one of the most studied choices for stem cell treatment [44]. (3) Decreases in the amount of stem cells in some experimental models of skin wound have been reported. Wu et al. observed a rapid decrease in stem cell survival 14 days after induction of a wound [45]. Muhammad et al. reported decreased survival of transplanted AD-MSC in an animal model of a burn injury [28]. However, despite the poor function of transplanted AD-MSC at the wound site, the use of certain special pretreatment agents not only provided a good biological environment that enhances survival of the AD-MSC, but also promotes proliferation, differentiation, and paracrine abilities of these AD-MSCs [46]. PBM has been shown to increase the proliferation ratio of cultivated AD-MSC [29], and it is an effective tactic for preconditioning AD-MSC in a culture system prior to implantation [47]. PBM therapies are non-
intrusive, cost-effective modalities, and wise choice instruments for wound treatment. PBM-based clinical investigations could indicate novel areas for the use of PBM and MSCs as treatments.

In the current study, we observed that preconditioning diabetic AD-MSC with PBM significantly increased the survival of diabetic AD-MSC and significantly diminished PDT and the apoptosis rate of this group compared with the diabetic control AD-MSC group in vitro (Fig. 2). Our in vivo analysis showed that in terms of tensiometric and stereological evaluating methods, groups 2–5 had significantly improved tensiometric and stereological parameters of the wounds compared to the control group (all, \( p = 0.000 \)). The AD-MSC + PBM in vitro in vivo group was significantly better than the other groups in terms of these tensiometric and stereological parameters (all, \( p = 0.000 \)). The results indicated that preconditioning diabetic AD-MSC with PBM prior to transplantation of these AD-MSCs into the wound bed and subsequent treatment of the wounds with in vivo PBM could overcome the barriers to wound healing in a delayed healing wound. This group had the best outcomes from the different protocols of combined AD-MSC and PBM in the current study. These results were partly in line with those reported by Liu and Zhang and Liao et al. In a review article, Liu and Zhang concluded that conditioning with PBM provoked proliferation, differentiation, and paracrine release of MSCs for cardiac renewal therapy [25]. Liao et al. examined the impact of preconditioned human (h) AD-MSC with PBM (650 nm, 2–8 J/cm²) in an in vitro aging skin mouse model. They reported that preconditioned hAD-MSC with PBM markedly improved damaged skin. Liao et al. concluded that PBM was a persuasive bioenhancer of hAD-MSC and could stimulate the beneficial function of AD-MSC for treatment [27].

**Fig. 5** Comparison of bending stiffness (a) and stress high load (b), of the wounds in the experimental groups according to the LSD test. ***\( p < 0.001 \)
Here, we showed that although transplantation of diabetic AD-MSC accelerated the healing process of an ischemic, delayed healing, MRSA-infected wound, however, preconditioning of diabetic AD-MSC with PBM provided synergistic benefits. Accordingly, Muhammad et al. have shown that transplantation of AD-MSC accelerated the healing process of an acid burn wound. Preconditioning of the AD-MSC provided additional benefits [28].

From a clinical perspective, the key challenge will be translating insights from hair follicle (HF) biology into treatment of disorders such as wound healing and tissue regeneration, as well as de novo induction of HFs in adult human skin. Since the HF and its surrounding mesenchyme are potent sources of multipotent stem cell populations, this raised the hope for the application of stem cells within adult human HFs in regenerative medicine [48]. Recent studies have shown that stem cells...
residing in HFs are able to contribute in reepithelialization and wound closure in vivo [48, 49]. We did not directly study the role of stem cells from wound adjacent HF in the wound closure. Inhibiting the wound closure of skin muscle through applying a ring frame around the wound iterated prominent regenerative role of keratinocytes, and adjacent HF stem cells. Accordingly, wound closure in groups 3–5 was significantly better than groups 1 and 2. At the same time, the results of group 5 were significantly better than other groups. It means that in terms of wound closure, the combined application of preconditioned diabetic AD-MSC with PBM in vitro plus PBM therapy in vivo has a significantly superior effect compared to the other treatments.

In the present study, we observed that an anti-inflammatory agent and a mitogenic agent, PBM [20], exhibited a synergistic effect on diabetic AD-MSC induced wound healing in vivo [35]. Diabetic AD-MSC alone significantly induced an anti-inflammatory effect when compared with groups 1, 3, and 4. Our results also demonstrated a significantly decreased inflammatory response after treatment with PBM preconditioned diabetic AD-MSC plus PBM in vivo (group 5) compared to treatment with AD-MSC alone. The improved proliferative activity (increased fibroblast counts) in the wound bed of the diabetic AD-MSC was specifically increased after preconditioning with PBM (Fig. 6).

In terms of bactericidal impact, treatment with only diabetic AD-MSC was not effective (Fig. 3). We observed that the combination of AD-MSC + PBM in vitro was significantly superior to treatment with only AD-MSC with regard to wound closure rate at day 8 and stress high load, bending stiffness, fibroblast counts, and bactericidal effects. These findings have implied that although the appropriate PBM protocol administered in vitro could facilitate the repair capabilities of transplanted diabetic AD-MSC in a DM1 model of an MRSA-infected wound and accelerate the wound healing process, the combined AD-MSC + PBM in vitro + in vivo (group 5) was significantly superior. In total, these results suggested that preconditioning with PBM, which is a cost-effective [50], anti-inflammatory, and mitogen agent [20], could be a powerful supplement for diabetic AD-MSC-based therapy in treating DFUs.

While diabetic rats lost significantly their weight after STZ injection in vivo part, we could not hold them for more than 21 days before surgery. This is considered as a limitation of our work. As we mentioned in the study design, wound closure rate, microbial examination and CFU counts, wound strength, and stereological tests were performed in each wound of rats, so we decreased the number of rats four folds in the current study and save the life of many animals.

Previously, co-treatment of AD-MSC with decellularized extracellular matrices (ECM) [49], and stromal vascular fraction (SVF) of nanofat [50] have been examined on several complications such as DFUs and scars. The data recommended the safety and efficiency of allogenic AD-MSC and ECM engraftments with no prominent complications [49]. There was also an encouraging relationship between SVF yield and medical effects in the nanofat treatment of scars [50]. In the lack of a uniform technique, renewing allogenic treatments by decellularized ECM would be tough, if not just untrustworthy [49]. Applying nanofat for curing scars requires more attention in terms of the medical ethic issue as well. Under conditions [49]. Applying nanofat for curing scars requires more attention in terms of the medical ethic issue as well. Under conditions
et al. observed that at long-term follow-up, Nevelia had a better clinical outcome, more angiogenesis, and tissue regeneration compared with Integra [53]. In another investigation, De Angelis et al. reviewed the surgical results of 20 patients, who experienced the application of Dermal Regeneration Template (DRT) for scalp reconstruction for minor defects. During 3 weeks, De Angelis et al. observed the complete healing of the wound bed by secondary intention with suitable cosmetic outcomes and firm scars [54]. Currently, no consistent technique for the extraction of adipose tissue exists. Consequently, Gentile et al. stated that autologous therapies using adipose-derived stromal vascular fraction (AD-SVF) and AD-MSCs warrant careful preparation for being harvested from adipose tissue. Gentile et al. suggested some quantitative and qualitative standards for extracting adipose tissue. Gentile et al. found that the discovery of new critical quality attributes (CQAs) of AD-MSCs evolves with respect to purity and potency. Adjustments to these benchmark standards will hopefully isolate AD-MSCs of various CQAs with greater reproducibility, quality, and safety. However, confirmatory studies undoubtedly need to be completed [55]. In the last study, De Angelis et al. treated 35 patients who suffered from chronic vascular ulcers with Nevelia® followed by autologous dermal-epidermal graft (DEG). De Angelis et al. found that the medical findings of the Nevelia group were better than the control group. Correlated histological and medical findings showed a better skin regeneration with a new formed tissue architecture analog to normal physiology of the skin in the Nevelia group [56].

It is necessary to improve and expand this field in a way that stem cell therapy and biotechnology can be applied cooperatively by adding different in vitro and in vivo applications of AD-MSCs, SVFs, and autologous growth factors like to PRP in tissue regeneration. For this reason, in spite of animal studies, it is necessary to report the application of SVFs and AD-MSCs in improving wound healing when utilized alone or in combination with HA, PRP, and fat graft, in humans. These experiments should focus on improving wound healing in humans as in vitro and pre-clinical conducted studies.

MSC-based therapeutics offers a novel approach toward chronic non-healing wounds. Stem cells exert their effects primarily through cytokine signaling. Combined secretion of growth factors and cytokines has been shown to promote wound repair. This combination of growth factors and cytokines successfully reduces inflammation and promotes angiogenesis, fibroblast migration, and collagen production as we observed in the current work. This environment contributes to healing and improves underlying pathologies, decreasing the recurrence of wounds and ulcers [51]. Stem cell proliferation and signaling play crucial roles in every phase of the wound healing process. Chronic wounds are often associated with impaired stem cell function. Although widespread adoption of stem therapy has been complicated by the costs and complications associated with large-scale production of cell products, cell-based therapy for non-healing wounds is a field with great potential. Increased population ages and the number of diabetic patients have increased the costs of chronic wound care. Improving new treatment strategies would help the patient to cope with this situation [51, 52].

While many of current treatment protocols for the management of wounds and ulcers are expensive and invasive [53], PBM techniques, in the shape of multipurpose light devices, are a noninvasive, economical, and attractive tool for wound management [25].

Many reports showed AD-MSC-based cell therapy products have optimal efficacy and efficiency in some clinical indications in both autologous and allogeneic purposes. Hence, they are being considered as potential tools for replacing, repairing, and regenerating dead or damaged cells. In this section, the therapeutic advancement of AD-MSCs in comparison to bone marrow (BM) MSC and some old reconstructive surgery methods were analyzed. AD-MSCs from adipose tissue and buccal fat pad, as easily harvestable and accessible sources, have gained interest to be used for some reconstructive surgeries and bone regeneration in the maxillofacial region and other parts of the body [54]. However, bone marrow mesenchymal stem cells (BMMSC) harvesting is a highly invasive and painful procedure implying general anesthesia and many days for hospital care. BMMSCs constitute a rare population, with only 0.002% of the total stromal cell population, and their isolation depends on the patient status and the volume of aspirates. AD-MSCs are currently isolated from the subcutaneous adipose tissue, which allows the rapid procurement of large numbers of highly active cells. The SVF harbor nearly 2% of AD-MSCs which is one of the greatest amounts in all tissues. These AD-MSC features seem to promote tissue repair while cell proliferation, angiogenesis, and anti-inflammatory processes are rapidly required in damaged sites [55]. In the management of mammary asymmetries by plastic and reconstructive surgeries, postoperative complications such as prolonged pain, hematomas, secondary cysts, infections, necrosis, capsular contracture, hypertrophic scars, and reinervention for prosthesis substitution were documented [56]. Major complications of microsurgical reconstruction of fingers such as lack of osseous integration of the implant, rare detachment of the prosthesis, or lack of acceptance by the patient were recorded as well [57]. Besides, in nasal reconstructive surgery, autologous bone grafts do not survive as well as cartilage grafts. Totality, satisfying esthetic results were achieved for both patient and surgeon in 79% of cases [58].
Conclusions
Preconditioning diabetic AD-MSC with PBM in vitro significantly increased cell function compared with the control diabetic AD-MSC. PBM preconditioning of diabetic AD-MSC significantly increased healing in ischemic MRSA-infected delayed healing wound in rats with DM1 compared to the control, control AD-MSC, and AD-MSC plus PBM in vivo groups. The combined application of preconditioned diabetic AD-MSC with PBM in vitro plus PBM therapy in vivo demonstrated a significant superior effect compared to the other groups.

The cellular and molecular mechanisms of combined PBM and AD-MSC treatment on inflammation and proliferation steps of delayed wound healing of DM animals should be clarified by additional investigations. We also suggest further research with a combination of AD-MSC, PBM, and scaffolds or DS in diabetic subjects.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13287-020-01967-2.

Abbreviations
DM: Diabetes mellitus; DFU: Diabetic foot ulcer; MRSA: Methicillin-resistant Staphylococcus aureus; EPC: Endothelial progenitor cell; AD-MSCs: Adipose-derived mesenchymal stem cells; PBM: Photobiomodulation; HIF-1α: Hypoxia-inducible factor-1 alpha; DM2: Type two diabetes mellitus; MSC: Mesenchymal stem cell; DM1: Type 1 diabetic rats; PDT: Population doubling time; CFU: Colony-forming unit; IP: Intraperitoneal; STZ: Streptozotocin; CD: Cluster of differentiation markers; AO: Acridine orange; EB: Ethidium bromide; H&E: Hematoxylin and eosin; SD: Mean ± standard deviation; ANOVA: One-way analysis of variance; LSD: Least significant difference; AGEs: Advanced glycosylation end products; h: Human; HF: Hair follicle; ECM: Extracellular matrices; SVF: Stromal vascular fraction; PRP: Platelet-rich plasma; DS: Dermal substitute; HA: Hyaluronic acid; DRT: Dermal Regeneration Template; AD-SVF: Adipose-derived stromal vascular fraction; COAs: Critical quality attributes; DEG: Dermal epidermal graft; BM: Bone marrow

Acknowledgements
The authors thank Mrs. Kim Vagharfard for her good job grammar editing of this article.

Authors’ contributions
Mohammad Bayat researched the data, managed the experiment, and wrote the manuscript. Houssein Ahmadi, Roohollah, Ebrahimpour-malekshah, Mostafa Neshat Ghallaf, Matin Abrisham, Fatemeh Zare, Atarosdadat Mostafavi-nia, Fatemehalsadat Rezaei, and Abdullah Amini performed the experiments. Abdullah Amini, Fatemeh Fadaei Fathabady, and Richard Albright made some suggestions. Sufan Chien scientifically edited the manuscript. Seyed Kamran Ghorashi contributed to the data analysis and interpretation. The authors read and approved the final manuscript.

Funding
Dr. Mohammad Bayat and Mr. Houssein Ahmadi paid from their pocket for this paper. SUMMUS Medical Laser in part financially supported this paper. Dr. Chien was supported in part by NIH grant DK105692.

Availability of data and materials
Some more information about the results, as well as statistical analyses of in vitro test, tensiometrical, and wound closure rate, is provided in Additional file 1.

Ethics approval and consent to participate
It was mentioned in the “Materials and methods” section.

Consent for publication
It was not applicable.

Competing interests
The authors declare that they have no conflicts of interest.

Author details
1Department of Biology and Anatomical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2Department of Anatomy, Faculty of Medicine, Tehran Medical sciences, Islamic Azad University, Tehran, Iran. 3University of Kentucky, College of Pharmacy 789 South Limestone Lexington, Kentucky 40536, USA. 4SUMMUS Medical Laser, 1185 W. Main St, Franklin, TN 37064, USA. 5Department of Statistics, Qom University, Qom, Iran. 6Price Institute of Surgical Research, University of Louisville, and Noveratech LLC, Louisville, KY, USA.

Received: 10 September 2020 Accepted: 7 October 2020
Published online: 25 November 2020

References
1. Atlas D. International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.

2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.

3. Cho N, Shaw J, Karuranga S, Huang Y, da Rocha FJ, Oktaroglu A, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.

4. Alexiadou K, Doupis J. Management of diabetic foot ulcers. Diabetes Ther. 2012;3(4).

5. Daia Paola L, Carone A, Ricci S, Russo A. Advances in treatment of diabetic foot ulcers. Avances en Diabetología. 2010;26(5):296–305.

6. Boulton AJ, Armstrong DG, Kinsner RS, Attinger CE, Lavery LA, Lipsky BA, et al. Diagnosis and management of diabetic foot complications. 2018.

7. Eleftheriadou I, Tentolouris N, Argiara V, Jude E, Boulton AJ. Methicillin-resistant Staphylococcus aureus in diabetic foot infections. Drugs. 2010;70(14):1785–97.

8. Lipsky BA. Diabetic foot infections: current treatment and delaying the ‘post-antibiotic era’. Diabetes Metab Res Rev. 2016;32:246–53.

9. Baitzis D, Eleftheriadou I, Veves A. Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Adv Ther. 2014;31(8):817–36.

10. Clayton W, Elasy TA. A review of the pathophysiology, classification, and treatment of foot ulcers in diabetic patients. Clin Diab. 2009;27(2):52–8.

11. Davis FM, Kimball A, Boniakowski A, Gallagger K. Dysfunctional wound healing in diabetic foot ulcers: new crossroads. Curr Diab Rep. 2018;18(1):2.

12. Catrina SB, Zheng X. Disturbed hypoxic responses as a pathogenic mechanism of diabetic foot ulcers. Diabetes Metab Res Rev. 2016;32(Suppl 1):179–85.

13. Jeffcoat WJ, Vliekkyte L, Boyko EJ, Armstrong DG, Boulton AJ. Current challenges and opportunities in the prevention and management of diabetic foot ulcers. Diabetes Care. 2018;41(4):645–52.

14. Gadelkarim M, Abushouk AI, Ghaneem E, Hamad AM, Saad AM, Abdal-Daim MM. Adipose-derived stem cells: effectiveness and advances in delivery in diabetic wound healing. Biomed Pharmacother. 2018;107:625–33.

15. Sumi M, Sata M, Toya N, Yanaka K, Ohki T, Nagai R. Transplantation of adipose stromal cells, but not mature adipocytes, augments ischemia-induced angiogenesis. Life Sci. 2007;80(6):559–65.

16. Burdon TJ, Paul A, Noesinik P, Prakash S, Shum-Tim D. Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential. Bone Marrow Res. 2011;2011:207326. https://doi.org/10.1155/2011/207326.

17. Cerqueira MT, Pircapo RP, Marques AP. Stem cells in skin wound healing: are we there yet? Adv Wound Care. 2016;5(4):164–75.

18. van de Vyver M. Intrinsic mesenchymal stem cell dysfunction in diabetes mellitus: implications for autologous cell therapy. Stem Cells Dev. 2017;26(14):1042–53.
19. Shin L, Peterson DA. Impaired therapeutic capacity of autologous stem cells in a model of type 2 diabetes. Stem Cells Transl Med. 2012;1(2):125–35.

20. Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. J Photochem Photobiol B. 2017;174:337–61.

21. Amiri A, Pourian R, Abdollahi-M A, Abbassenad-HA, Ghoreishi SK, Chien S, et al. Stereological and molecular studies on the combined effects of photobiomodulation and human bone marrow mesenchymal stem cell conditioned medium on wound healing in diabetic rats. J Photochem Photobiol B. 2018;182:42–51.

22. Cury V, Moretti AIS, Assis L, Bossini P, de Souza CJ, Neto CB, et al. Low level laser therapy increases angiogenesis in a model of ischemic skin flap in rats mediated by VEGF, HIF-1α and MMP-2. J Photochem Photobiol B. 2013;125:164–70.

23. Moradi A, Zare F, Mostafavi-A A, Safaji S, Shahbaz A, Habibi M, et al. Photobiomodulation plus adipose-derived stem cells improve healing of ischemic infarcted wounds in type 2 diabetic rats. Sci Rep. 2020;10(1):2106.

24. AlGhamdi KM, Kumar A, Moussa NA. Low-level laser therapy: a useful technique for enhancing the proliferation of various cultured cells. Lasers Med Sci. 2012;27(1):237–9.

25. Liu Y, Zhang H. Low-level laser irradiation precondition for cardiac regenerative therapy. Photomed Laser Surg. 2016;34(11):572–9.

26. Ebrahimpour-Malekshah R, Amiri A, Zare F, Mostafavi-A A, Davoody S, Daravi N, Rahmani M, Hashemi SM, Habibi M, Ghoreishi SK, Chien S, Shafikhani S, Amrifi H, Bayat S, Bayat M. Combined therapy of photobiomodulation and adipose-derived stem cells systemically improve healing in an ischemic, infected and delayed healing wound model in rats with type 1 diabetes mellitus. BMJ Open Diabetes Res Care. 2020;8(1):e001033. https://doi.org/10.1136/bmjdrc-2019-001033. PMID: 32098988; PMCID: PMC7206914.

27. Liao X, Li SH, Xie GH, Xie S, Xiao LL, Song JX, et al. Preconditioning with low-level laser irradiation enhances the therapeutic potential of human adipose-derived stem cells in a mouse model of photoaged skin. J Photochem Photobiol B. 2019;201:111658.

28. Muhammad G, Xu J, Bulte JWM, Jablonska A, Walczak P, Janowski M. Concise review: TLR pathway-miRNA interplay during adipose-derived stem cells in a mouse model of photoaged skin. J Photochem Photobiol B. 2019;201:111658.

29. Liu Y, Zhang H. Low-level laser irradiation precondition for cardiac regenerative therapy. Photomed Laser Surg. 2016;34(11):572–9.

30. Cañedo-Dorantes L, Cañedo-Ayala M. Skin Acute Wound Healing: A Comprehensive Review. Int J Inflam. 2019;2019:3706315. https://doi.org/10.1155/2019/3706315. PMID: 31275545; PMCID: PMC6582859.

31. Lopes L, Setia O, Aurshina A, Liu S, Hu H, Isaji T, et al. Stem cell therapy for wound care: a potent, noninvasive, photoceutical approach. Adv Skin Wound Care. 2019;32(4):157–67.

32. Ansell DM, Kloepper JE, Thomason HA, Paus R, Hardman MJ. Exploring the "hair growth-wound healing connection": anagen phase promotes wound re-epithelialization. J Invest Dermatol. 2011;131(5):18–28.

33. Shin L, Peterson DA. Impaired therapeutic capacity of autologous stem cells in a model of type 2 diabetes. Stem Cells Transl Med. 2012;1(2):125–35.

34. Dehkordi AN, Babaheydari FM, Chehelgerdi M, Dehkordi SR. Skin tissue regeneration and regeneration. Expert Opin Biol Ther. 2015;15(9):1285–92.

35. Young SR, Dyson M. Effect of therapeutic ultrasound on the healing of full-thickness excised skin lesions. Ultrasound. 1990;28(3):175–80.

36. Cañedo-Dorantes L, Cañedo-Ayala M. Skin Acute Wound Healing: A Comprehensive Review. Int J Inflam. 2019;2019:3706315. https://doi.org/10.1155/2019/3706315. PMID: 31275545; PMCID: PMC6582859.

37. Lopes L, Setia O, Aurshina A, Liu S, Hu H, Isaji T, et al. Stem cell therapy for wound care: a potent, noninvasive, photoceutical approach. Adv Skin Wound Care. 2019;32(4):157–67.

38. Ansell DM, Kloepper JE, Thomason HA, Paus R, Hardman MJ. Exploring the “hair growth-wound healing connection”: anagen phase promotes wound re-epithelialization. J Invest Dermatol. 2011;131(5):18–28.

39. Sen CK. Human wounds and its burden: an updated compendium of estimates. Adv Wound Care (New Rochelle). 2019;8(2):39–48. https://doi.org/10.1089/wound.2019.0946.

40. Petersen DA. Impaired therapeutic capacity of autologous stem cells in a model of type 2 diabetes. Stem Cells Transl Med. 2012;1(2):125–35.

41. Rezai Rad M, Bohloli M, Akhavan Bahrami M, Anbarlou A, Nazeman P, Khosjasteh A. Impact of tissue harvesting sites on the cellular behaviors of adipose-derived stem cells implication for bone tissue engineering. Stem Cells Int. 2017;2017:2156478. https://doi.org/10.1155/2017/2156478. Epub 2017 Dec 14. PMID: 29387089; PMCID: PMC5745705.

42. Maitini L, Rochette L, Amine M, Malka G. Regenerative capacity of Adipose Derived Stem Cells (ADSCs), comparison with Mesenchymal Stem Cells (MSCs). Int J Mol Sci. 2019 May 22;20(10):2523. https://doi.org/10.3390/ijms20102523. PMID: 31121953; PMCID: PMC6566837.

43. Aroca A, Gravante G, Aroca F, Gentile P, Castri F, Delogu D, et al. Breast asymmetries: a brief review and our experience. Aesthet Plast Surg. 2006;30(3):309–19.

44. Cervelli V, Bottini DJ, Arpin A, Grimaldi M, Rogliani M, Gentile P. Bone-anchored implant in cosmetic finger reconstruction. Ann Chir Plast Esthet. 2008;53(4):365–7. https://doi.org/10.1016/j.anplas.2007.06.010.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.